IGF-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-12 and is reviewed periodically as new material appears.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Given this uncertainty, between April–May 2006 at the JINR, a FLNR–PSI team conducted experiments probing the synthesis of this isotope as a daughter in the nuclear reaction 242Pu(48Ca,3n)287Fl. (The 242Pu + 48Ca fusion reaction has a slightly larger cross-section than the 238U + 48Ca reaction, so that the best way to produce copernicium for chemical experimentation is as an overshoot product as the daughter of flerovium.) In this experiment, two atoms of copernicium-283 were unambiguously identified and the adsorption properties were interpreted to show that copernicium is a more volatile homologue of mercury, due to formation of a weak metal-metal bond with gold. This agrees with general indications from some relativistic calculations that copernicium is "more or less" homologous to mercury. However, it was pointed out in 2019 that this result may simply be due to strong dispersion interactions. In April 2007, this experiment was repeated and a further three atoms of copernicium-283 were positively identified. The adsorption property was confirmed and indicated that copernicium has adsorption properties in agreement with being the heaviest member of group 12. These experiments also allowed the first experimental estimation of copernicium's boiling point: 84+112−108 °C, so that it may be a gas at standard conditions. Because the lighter group 12 elements often occur as chalcogenide ores, experiments were conducted in 2015 to deposit copernicium atoms on a selenium surface to form copernicium selenide, CnSe.
== History == Humans have inhabited the atoll since about 1,000 B.C. The islands were first settled by Austronesian islanders. The first European colonizers to Enewetak, Spanish explorer Álvaro de Saavedra Cerón, arrived on 10 October 1529. He called the island "Los Jardines" (The Gardens). In 1794, sailors aboard the British merchant sloop Walpole called the islands "Brown's Range" (thus, the Japanese name "Brown Atoll"). It was visited by about a dozen ships before the establishment of the German colony of the Marshall Islands in 1885.
Rusfertide, sold under the brand name Mimrylo, is a medication used for the treatment of polycythemia vera. It is a hepcidin mimetic. It was developed by Protagonist Therapeutics in partnership with Takeda Pharmaceuticals. It is given by subcutaneous injection. The most common adverse reactions include injection site reactions and anemia. Rusfertide was approved for medical use in the United States in August 2026. It is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that naturally regulates iron in the body.
Sources: en.wikipedia.org
==== Chemical ==== Nitrous acid can be used to chemically depolymerize heparin/HS. Nitrous acid can be used at pH 1.5 or a higher pH of 4. Under both conditions, nitrous acid effects deaminative cleavage of the chain. At both 'high' (4) and 'low' (1.5) pH, deaminative cleavage occurs between GlcNS-GlcA and GlcNS-IdoA, albeit at a slower rate at the higher pH. The deamination reaction, and therefore chain cleavage, is regardless of O-sulfation carried by either monosaccharide unit. At low pH, deaminative cleavage results in the release of inorganic SO4, and the conversion of GlcNS into anhydromannose (aMan). Low-pH nitrous acid treatment is an excellent method to distinguish N-sulfated polysaccharides such as heparin and HS from non N-sulfated polysaccharides such as chondroitin sulfate and dermatan sulfate, chondroitin sulfate and dermatan sulfate not being susceptible to nitrous acid cleavage.
=== Phase 2 === Cannabidiol (CBD; ATL5; RLS103) – cannabinoid receptor modulator and other actions Cannabidiol (CBD; Empower CBD) – cannabinoid receptor modulator and other actions ENX-102 (ENX102) — α2, α3, and α5 subunit-containing GABAA receptor positive allosteric modulator and nonbenzodiazepine FKW00GA (FKW-00GA; TGW-00AA; TGW00AA) – serotonin 5-HT1A receptor partial agonist and serotonin 5-HT2A receptor antagonist JNJ-42165279 (JNJ-5279) – fatty acid amide hydrolase (FAAH) inhibitor (R)-Midomafetamine ((R)-MDMA; R-MDMA; EMP-01) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen Non-racemic MDMA (ALA-002; 70–80% (R)-MDMA, 20–30% (S)-MDMA) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen NTX-1472 (RO-6953958) – vasopressin V1A receptor antagonist ONO-1110 – endocannabinoid synthesis regulator and indirect cannabinoid receptor modulator [3] [4] [5] Oxytocin (intranasal potentiated oxytocin; TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist Vilazodone (Viibryd) – serotonin 5-HT1A receptor partial agonist and serotonin reuptake inhibitor
== Cellular immunotherapy == Immune cell-based therapies for solid tumors may be limited by tumor-antigen heterogeneity, restricted immune-cell trafficking, an immunosuppressive tumor microenvironment, limited cell persistence, treatment-related toxicities, and complex manufacturing requirements.
Deranged – A more extreme version of Eccentric as implied in The Hydrogen Sonata Minds' names Minds (and, as a consequence, Culture starships) usually bear names that do a little more than just identify them. The Minds themselves choose their own names, and thus they usually express something about a particular Mind's attitude, character or aims in their personal life. They range from funny to just plain cryptic. Some examples are:
Sources: en.wikipedia.org
== Operation == According to Swedish journalist Bertil Lintner, the restaurants are one of several overseas business ventures of Room 39, a North Korean government organization dedicated to acquiring and laundering foreign currency for the North Korean leadership. North Korean defectors have reported that the restaurants are run by local middlemen, who are required to send money every year to the North Korean government. The North Korean staff, who live on the restaurant premises, are said to be thoroughly screened for political loyalty and to be closely watched by on-site North Korean security agents. In the 2000s, according to Daily NK, several attempted escapes by waitresses in China led to the closure of several restaurants and the repatriation of the staff. In 2016, Chinese authorities announced that 13 restaurant workers had defected from Pyongyang restaurants in China to South Korea.
The pain in an osteoarthritic joint has been related to thickened synovium and to subchondral bone lesions. The inflammation of the joint lining (synovium) in osteoarthritis is characterized by involving macrophages via activation of the innate immune system (as compared to T-cell activation in the joint lining of people with rheumatoid arthritis). Pro-inflammation cytokines in osteoarthritis stimulate matrix metalloproteinases which leads to degradation and remodeling of the joint. Tissue damage or degradation of the articular cartilage or synovium leads to further release of inflammatory cytokines, driving the process.
Datura arenicola Gentry ex Bye & Luna Datura ceratocaula Ortega Datura discolor Bernh. Datura ferox L. Datura innoxia Mill. Datura kymatocarpa Barclay Datura lanosa A.S.Barclay ex Bye Datura leichhardtii Benth. Datura metel L. Datura pruinosa Greenm. Datura quercifolia Kunth Datura reburra Barclay Datura stramonium L. Datura wrightii Regel Of the above, D. leichhardtii is close enough to D. pruinosa to merit demotion to a subspecies and likewise D. ferox and D. quercifolia are close enough in morphology to merit being subsumed in a single species. Furthermore, the Australian provenance of D. leichhardtii, the Chinese provenance of D. ferox, and the Afro-Asiatic provenance of D. metel have been cast into serious doubt, with the three species being almost certainly post-Columbian introductions to the regions to which they were originally thought native. The case of D. metel is unique in that not only is the plant not a true species at all, but an assemblage of ancient pre-Columbian cultivars created from D. innoxia in the Greater Antilles, but evidence is mounting that it was introduced to the Indian subcontinent no later than the second century CE—whether by natural or human agency is, as yet, unknown—making it one of the most ancient plant introductions (if not the most ancient) from the New World to the Old World (see Columbian Exchange). D. arenicola is a recently discovered species, described first in 2013, of very restricted range, and so distinctive as to have merited the creation for it of the new section Discola [not to be confused with the species name D.
The low levels of progesterone with oral progesterone may also explain its differences in risk of breast cancer and venous thromboembolism relative to progestogens when added to estrogen therapy in postmenopausal women. Such risks are increased by progestins, which are PR agonists similar to progesterone, but have been found to be increased less or not at all by oral progesterone. Since typical clinical doses of oral progesterone achieve very low levels of progesterone, and progesterone therapy with luteal-phase progesterone levels has never been properly evaluated in sufficiently large clinical studies, it has been said that notion that progesterone somehow differs from progestins and does not increase the risk of breast cancer or venous thromboembolism is unsubstantiated. Moreover, in the absence of adequate data to the contrary, it would be reasonable to consider progesterone at least equivalent to progestins as a potential risk factor for such complications. Indeed, preclinical research suggests a carcinogenic role for progesterone in the breast, and the French E3N study observed a significantly higher risk of breast cancer with estrogen and oral progesterone therapy in postmenopausal women after long-term (>5-year) administration. This is potentially consistent with a weak proliferative effect of oral progesterone on the breasts such that a longer duration of exposure may be necessary for an increase in breast cancer risk to manifest.
=== 4 September === One person was killed in an SAF drone strike on a market in Manawashi, South Darfur. The drone responsible was shot down by the RSF over Mershing, with RSF commanders claiming that it was a Baykar Bayraktar Akıncı drone.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.